After 26,657 shares were withheld for taxes, David Hallett directly held 1,017,180 Recursion (RXRX) shares.
Recursion Pharmaceuticals, Inc. (RXRX) reported that Chief Scientific Officer David Hallett had 26,657 Class A common shares withheld for tax obligations on November 16, 2026. This transaction was related to the net settlement of restricted stock units, with the shares valued at $3.1850 each. Following this withholding, Hallett's direct holdings in the company amount to 1,017,180 shares.
After 25,018 shares were withheld for taxes, Recursion (RXRX) CFO Ben R. Taylor held 1,046,444 shares directly.
Recursion Pharmaceuticals, Inc. CFO Ben R. Taylor had 25,018 Class A common shares withheld on November 16, 2026, to cover tax obligations related to restricted stock units. After this transaction, he directly held 1,046,444 shares. The transaction was reported with a per-share price of $3.185.
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Recursion Pharmaceuticals announced alignment with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to enroll approximately 200 adults and begin in the second half of 2027, will count the removal of adenomas 10 mm or larger as a clinical event in the primary endpoint. This regulatory milestone addresses a $15 billion market opportunity for a condition with no approved drug options.
Recursion Pharmaceuticals stock hits 52-week low at 2.76 USD
Recursion Pharmaceuticals Inc. (RXRX) stock recently plunged to a 52-week low of $2.77, marking an 18% decline over the past week and a 29.5% drop over the year. Despite the downturn, the company reported strong Q3 2026 revenue of $18.55 million, exceeding forecasts, while adjusted loss per share aligned with estimates. InvestingPro analysis suggests the stock is trading below its Fair Value and holds more cash than debt, though it is rapidly burning through cash.
Recursion Pharmaceuticals Director Fred Hassan Receives 156,658 RSUs Under Compensation Policy
Fred Hassan, a Director at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), was granted 156,658 restricted stock units (RSUs) on November 2, 2026, as part of the company's Outside Director Compensation Policy. These RSUs were acquired at no cost and will vest in equal thirds over the first three anniversaries of the grant date, contingent on his continued service. Following this transaction, Hassan directly and beneficially owns 156,658 shares of Class A Common Stock.
A director plans to sell 40,000 Recursion (NASDAQ: RXRX) shares through Fidelity.
Recursion Pharmaceuticals, Inc. (RXRX) director Blake C. Borgeson plans to sell 40,000 Class A shares with an aggregate market value of $155,200 through Fidelity Brokerage Services LLC. These shares are identified as Founders Shares acquired as compensation in 2017. The filing also reports three previous Class A share sales by Borgeson in the past three months.
Recursion Pharmaceuticals, Inc. Class A Estimates – BX:RXRX
The article provides an overview of Recursion Pharmaceuticals, Inc. (RXRX) listed on BX Swiss, focusing on its financial actuals and analyst estimates. It highlights access to reported financial data across income statement, balance sheet, cash flow statement, and valuation metrics, allowing users to compare actual results with average, high, and low estimates. The platform also offers tools to visualize trends over time for both annual and quarterly data.
Weekly Recap: Filed $200M follow-on offering and REC-4881 87% polyp cut
Recursion Pharmaceuticals (RXRX) completed a $200M follow-on offering, increasing its cash reserves to an estimated $561M and extending its cash runway into 2029. The company also released positive Phase 1b/2 TUPELO data for REC-4881, showing an 87% reduction in total GI polyp burden, and promising Phase 1 DAHLIA results for REC-1245 in oncology. A registrational trial for REC-4881 is planned for H2 2027.
Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Know
Recursion Pharmaceuticals (RXRX) shares are trending after announcing a $200 million stock offering priced at $3.25 per share. Separately, Sanofi exercised an option on a Recursion drug candidate, triggering a $10 million milestone payment and bringing total payments from Sanofi to $144 million. The candidate, an oral small molecule for inflammatory diseases, is expected to enter Phase 1 trials in 2027.
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Pharmaceuticals (NASDAQ: RXRX) has announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at $3.25 per share, aiming to raise approximately $200 million. The offering, expected to close around October 16, 2026, includes participation from several leading healthcare and institutional investors. Leerink Partners, Goldman Sachs, Morgan Stanley, and Evercore Group are acting as joint bookrunning managers.
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at $3.25 per share, aiming to raise approximately $200 million in gross proceeds. The offering, expected to close around October 16, 2026, includes participation from major healthcare and institutional investors. Leerink Partners, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, and Evercore Group L.L.C. are acting as joint bookrunning managers.
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Pharmaceuticals (NASDAQ: RXRX) announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at $3.25 per share, aiming to raise approximately $200 million in gross proceeds. The offering, expected to close around October 16, 2026, includes participation from major healthcare and institutional investors. Leerink Partners, Goldman Sachs, Morgan Stanley, and Evercore Group are acting as joint bookrunning managers.
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Recursion Pharmaceuticals, Inc. announced the pricing of an underwritten offering of 61,540,000 shares of its Class A common stock at $3.25 per share, aiming to raise approximately $200 million in gross proceeds. The offering is expected to close around October 16, 2026, with Leerink Partners, Goldman Sachs, Morgan Stanley, and Evercore Group acting as joint bookrunning managers. The financing included participation from several leading healthcare and institutional investors.
Weekly Recap: 33.5% short interest in NASDAQ:RXRX and ARK ETF holding
Recursion Pharmaceuticals, Inc. Class A (NASDAQ: RXRX) is experiencing significant short interest, with approximately 33.5% of its shares outstanding being shorted, ranking it third among highly shorted stocks. Despite this, the ARK Genomic Revolution ETF continues to maintain its investment in the AI-driven biopharma company. Analysts are closely watching RXRX, noting its target prices and potential near-term earnings volatility.
A director sells 25,000 shares at $5 after exercising options at $2.22 at Recursion (RXRX).
Recursion Pharmaceuticals, Inc. director Robert Hershberg exercised options for 25,000 Class A common shares at $2.22 per share and subsequently sold those shares at $5.00 per share on October 6, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted in December 2025. After the sale, Hershberg's reported option position covered 500,000 shares with a $2.22 exercise price and a March 19, 2030 expiration date.
Under a trading plan, Recursion (RXRX) director sells 50,000 shares averaging $4.84 each.
Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 50,000 shares of Class A common stock on October 6, 2026, at a weighted average price of $4.84 per share. This sale was conducted under a Rule 10b5-1 trading plan adopted in August 2025, with individual trades ranging from $4.80 to $5.00. Following this transaction, Borgeson's direct holdings in the company amount to 6,108,287 shares.
25,000 shares worth $125K are proposed for sale by Recursion (RXRX) director Robert Hershberg.
Recursion Pharmaceuticals, Inc. director Robert M. Hershberg has filed a notice for a proposed sale of 25,000 Class A shares, valued at $125,000. These shares were acquired through a stock option exercise and are intended to be sold for cash on October 6, 2026. The company currently has 535,342,170 shares outstanding.
Recursion Pharmaceuticals Director Hershberg to Sell 25,000 Shares via Option Exercise
Robert Hershberg, a Director at Recursion Pharmaceuticals, Inc., plans to sell 25,000 Class A shares valued at approximately $125,000. These shares were acquired through a stock option exercise on October 6, 2026, and the sale will be conducted under a Rule 10b5-1 trading plan established in December 2025. This transaction will be facilitated by Fidelity Brokerage Services LLC on NASDAQ.
A 50,000-share sale is proposed by director Blake C. Borgeson at Recursion (RXRX).
Recursion Pharmaceuticals, Inc. (RXRX) Director Blake C. Borgeson has filed a Form 144, indicating his intent to sell 50,000 Class A shares valued at $242,000 through Fidelity Brokerage Services LLC, with an approximate sale date of October 6, 2026. The filing also discloses Borgeson's previous sales of 40,000 shares on July 7, 2026, 30,000 shares on August 4, 2026, and 30,000 shares on September 1, 2026.
Recursion Pharmaceuticals, Inc. - Class A Common Stock (Nasdaq:RXRX) Stock Quote
This page provides a detailed stock quote for Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX), including its current trading price, volume, and performance metrics. It also features recent news headlines related to the company, focusing on its AI drug platform, financial results, and analyst opinions. The article details RXRX's performance against major market indices and provides answers to frequently asked questions about the stock.
Dean Y. Li receives 3,378 Recursion (RXRX) shares under its Outside Director Compensation Policy.
Recursion Pharmaceuticals director Dean Y. Li received 3,378 shares of Class A common stock on October 1, 2026, as an award under the company's Outside Director Compensation Policy. Following this transaction, Li directly holds 1,476,707 shares, with additional indirect holdings through two trusts totaling 1,422,048 shares in the Dean Y. Li Revocable Trust and 421,000 shares in the Dean Y. Li 2021 Family Trust. This information was disclosed in a Form 4 SEC filing.
A $0-per-share award brings Zavain Dar's direct Recursion (RXRX) holdings to 245,371 shares.
Recursion Pharmaceuticals director Zavain Dar received an award of 4,607 shares of Class A Common Stock on October 1, 2026, with a reported transaction price of $0.0000 per share. This award was issued under the company's Outside Director Compensation Policy. Following this transaction, Dar's directly held position in Recursion Pharmaceuticals is 245,371 shares.
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
Cantor Fitzgerald upgraded 4D Molecular Therapeutics (FDMT) to Buy with a $32.00 price target, citing a 105.5% upside. Bank of America Securities maintained a Hold rating on Recursion Pharmaceuticals (RXRX) with a $6.65 price target. JonesTrading reiterated a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM) with a $24.00 price target, noting a 63.8% upside.
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale
Recursion Pharmaceuticals (RXRX) CFO Ben R Taylor had 5,396 shares of Class A Common Stock withheld on September 15, 2026, to cover tax withholding obligations related to restricted stock units. This was not an open-market sale, and Taylor still holds over 1.07 million shares directly after this transaction. The shares were valued at $3.41 each for tax purposes.
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com
Najat Khan, CEO of Recursion Pharmaceuticals (NASDAQ:RXRX), sold 22,408 shares of Class A Common Stock for $78,822 on September 8, 2026, as part of a pre-arranged trading plan. This sale occurred while the stock price was down and concerns about the company's cash burn rates were noted by InvestingPro. Recursion Pharmaceuticals recently reported a Q2 2026 revenue shortfall and adjusted its full-year cash operating expense guidance downwards.
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan
Recursion's CEO and President, Najat Khan, sold 22,408 shares of Class A Common Stock on September 8, 2026, through a pre-planned Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $3.5176 per share, totaling approximately $79,000. Following this transaction, Khan directly holds 2,072,890 shares of RXRX.
Recursion Pharma CEO Najat Khan sells $78,822 in stock
Recursion Pharma CEO Najat Khan sold 22,408 shares of Class A Common Stock for $78,822 on September 8, 2026, through a Rule 10b5-1 trading plan. This transaction leaves Khan with 2,072,890 shares. The sale occurred as the stock trades nearly 13% down over the past week, although InvestingPro analysis suggests it is undervalued with a fair value of $3.92.
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan
Recursion Pharmaceuticals CEO and President Najat Khan sold 22,408 shares of Class A Common Stock on September 8, 2026, under a pre-established Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $3.5176, with individual trades ranging between $3.485 and $3.58. Following the transaction, Khan directly beneficially owns 2,072,890 shares.
Ex-Recursion (NASDAQ: RXRX) director plans new sale after 340K-share June trade
Former Recursion Pharmaceuticals director Christopher C. Gibson has filed to sell 77,290 Class A shares of RXRX, valued at $262,013.10, through Fidelity Brokerage Services. This upcoming sale, scheduled for August 21, 2026, follows several prior transactions by Gibson, the Gibson Family Trust, and Lahwran-3 LLC, including a significant sale of 340,440 shares on June 18, 2026. The filing provides detailed information on past sales and the regulatory context of Rule 144 for selling restricted securities.
Recursion (NASDAQ: RXRX) director sells 30,000 shares in planned trade
A director at Recursion (RXRX), Blake Borgeson, sold 30,000 Class A Common Stock shares on September 1, 2026, at an average price of $3.34 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. Following the sale, Borgeson still holds over 6.1 million shares of the company's Class A Common Stock.
Recursion (NASDAQ: RXRX) director eyes $100K stock sale after recent trades
Recursion Pharmaceuticals, Inc. (RXRX) director Blake Borgeson has filed a Form 144 indicating his intent to sell 30,000 Class A shares worth approximately $100,200 through Fidelity Brokerage Services LLC. The shares were originally acquired as Founder Shares on September 19, 2017. The filing also details prior sales made by Borgeson over the last three months, totaling 100,000 shares for over $360,000.
RXRX | Recursion Pharmaceuticals, Inc. Class Financials - Revenue Breakdown
This page provides a detailed financial overview of Recursion Pharmaceuticals, Inc. (RXRX), focusing on its revenue breakdown, alongside other financial data points like insider trading, institutional holdings, analyst ratings, and executive compensation. It notes the absence of specific revenue breakdown by segment or geography data and also lacks recent Congressional trading, corporate lobbying, and new patent grants. The article highlights the company's profile as a clinical-stage biotechnology firm and offers tools for advanced analysis.
Recursion Pharmaceuticals (RXRX) Is Down 5.5% After Q2 Revenue Drop And Narrower Losses - What's Changed
Recursion Pharmaceuticals (RXRX) saw a 5.5% drop after its Q2 2026 earnings report revealed a revenue decrease to US$7.67 million from US$19.22 million year-over-year, despite narrowing its net loss. The company's investment narrative continues to hinge on its AI-enabled drug discovery platform and advancing early-stage oncology trials, with analysts noting its potential for significant upside if clinical assets convert into successful drug programs. However, concerns remain regarding cash burn, reliance on external funding, and the need for future capital as R&D progresses.
Recursion (NASDAQ: RXRX) CFO has 25,018 shares withheld for taxes
Recursion (NASDAQ: RXRX) CFO Ben R. Taylor had 25,018 shares of Class A Common Stock withheld on August 17, 2026, to cover tax withholding obligations related to the net settlement of restricted stock units. The shares were valued at $3.16 each for this transaction. Following this event, Taylor directly holds 1,076,858 shares of Class A Common Stock.
Recursion (NASDAQ: RXRX) CSO sees 26K shares withheld for taxes
Recursion Pharmaceuticals (NASDAQ: RXRX) Chief Scientific Officer David Hallett had 26,657 shares of Class A common stock withheld on August 17, 2026, to satisfy tax obligations related to the net settlement of restricted stock units. This action was solely for tax purposes and not a market sale, reducing his direct holdings to 1,043,837 shares. The price per share for the tax withholding was $3.16.
Recursion (NASDAQ: RXRX) CEO's 80K shares withheld for RSU taxes
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) CEO Najat Khan had 80,498 shares of Class A Common Stock withheld on August 17, 2026, to cover tax obligations related to the net settlement of restricted stock units (RSUs). These shares were not sold in an open-market transaction, and after the withholding, Khan directly holds 2,095,298 shares. The value used for tax withholding was $3.16 per share.
Recursion Pharmaceuticals (RXRX) Stock Dropped, So What Is Behind The Move?
Recursion Pharmaceuticals (RXRX) recently reported its Q2 and H1 2026 results, showing lower sales but a narrower net loss, which impacted short-term stock sentiment. The company's stock experienced a 4.53% drop over one day, though some analysts see potential for future growth based on its AI healthcare focus and leadership changes. While one narrative suggests the stock is overvalued at $3.16 compared to a fair value of $1.97, a discounted cash flow model by Simply Wall St indicates it might be trading below an estimated future cash flow value of $9.80.
Recursion Pharmaceuticals (RXRX) Is Up 7.3% After Mixed Q2 Results With Narrower Net Loss
Recursion Pharmaceuticals reported mixed Q2 2026 results with a sharp revenue decline but a narrower net loss, indicating improved cost controls. The company's investment narrative remains tied to its AI-enabled drug discovery platform, requiring continuous R&D spending, external funding, and milestone payments. Despite reduced losses, future growth hinges on clinical progress and successful capital access, with analyst forecasts showing a wide range of potential outcomes.
Recursion Pharmaceuticals (RXRX) Stock Sinks As Cash Burn Dominates AI Drug Story
Recursion Pharmaceuticals (RXRX) saw its stock decline by 4% after reporting Q2 2026 revenue of US$7.67 million against a net loss of US$131.01 million, highlighting significant cash burn. Despite the financial losses, the company showed progress in its AI-driven drug discovery with clinical milestones and partnership validations. The market remains divided between the potential of its AI platform and concerns over its high cash burn and lack of immediate commercial products.
Recursion Pharmaceuticals (RXRX) director sells 30,000 shares in 10b5-1 plan
Recursion Pharmaceuticals (RXRX) director Blake Borgeson sold 30,000 shares of Class A Common Stock at $3.25 per share on August 4, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 31, 2025. Following the sale, Borgeson directly holds 6,188,287 shares of the company.
Recursion Pharmaceuticals (RXRX) Stock Looks Weak On Returns While Trading Above Fair Value
Recursion Pharmaceuticals (RXRX) stock has seen a significant decline over the past five years and is currently trading above its fair value based on various valuation checks. The company's P/S ratio of 30.7x is well above the biotech industry average, indicating it is expensive relative to its revenue. Despite a collaboration with Genentech, the stock's valuation remains a concern, with community opinions divided on its future prospects.
Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program
Recursion (Nasdaq: RXRX) announced its second-quarter 2026 financial results, highlighted by Genentech advancing the first neuroscience target from their collaboration into an early discovery program. This milestone validates Recursion's AI-native platform for identifying novel biological targets. The company also provided updates on its pipeline, including progress for REC-4881 in Familial Adenomatous Polyposis and the upcoming Phase 1/2 trial for REC-7735, and reduced its 2026 cash operating expense guidance.
Vanguard Capital Management (RXRX) discloses 26.7M-share, 5.09% holding in Recursion
Vanguard Capital Management LLC and its affiliates have disclosed a beneficial ownership of 26,744,129 shares, representing a 5.09% stake, in Recursion Pharmaceuticals Inc. (RXRX) as of June 30, 2026. This Schedule 13G filing indicates Vanguard has sole voting power over 3,978,189 shares and sole dispositive power over all 26,744,129 shares. The disclosure clarifies that no other single person has an interest exceeding 5% through Vanguard's holdings.
RXRX (NASDAQ: RXRX) insider plans 75,000-share Class A stock sale
An insider at Recursion Pharmaceuticals, Inc. (RXRX) has filed a Rule 144 notice to sell 75,000 Class A shares through Fidelity Brokerage Services LLC, valued at approximately $225,000. These shares were acquired as Founder Shares for compensation on April 20, 2021. The filing also details numerous previous Class A share sales by Christopher C. Gibson and affiliated entities from May to July 2026.
BlackRock (RXRX holder) discloses 8.5% ownership in Recursion Pharmaceuticals Class A shares
BlackRock, Inc. has filed an amended Schedule 13G disclosing an 8.5% passive ownership stake in Recursion Pharmaceuticals, Inc.'s Class A shares. This amounts to 44,541,605 shares, with BlackRock holding sole voting power over 43,812,201 shares and sole dispositive power over all 44,541,605 shares. The filing indicates that no single underlying client or investor holds more than five percent of the outstanding common shares.
RXRX (RXRX) holder files to sell 50,000 Class A shares after prior sales
A shareholder of Recursion Pharmaceuticals, Inc. (RXRX), associated with Christopher C. Gibson, has filed a Form 144 to sell 50,000 Class A shares valued at over $151,000. These shares are identified as Founders Shares initially acquired as compensation in April 2021. The filing also details numerous previous sales of Class A shares by Gibson and related entities over the past three months.
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BMV:RXRX
Recursion Pharmaceuticals, Inc. (BMV:RXRX) generated 1.34 billion Mexican Pesos in revenue last year. The majority of this revenue, 1.35 billion MXN, came from its Drug Discovery segment. The United States was the largest geographical contributor, accounting for 709.28 million MXN of the company's revenue.
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – SWB:8RL
This article provides a revenue breakdown for Recursion Pharmaceuticals, Inc. Class A (SWB:8RL), highlighting its top-performing segment and geographical contribution. Last year, the company generated 63.22 million EUR, with the Drug Discovery segment contributing 63.58 million EUR, and the United States accounting for 33.50 million EUR of the revenue.
Recursion Pharmaceuticals, Inc. Class A Revenue Breakdown – BIVA:RXRX
This article provides a revenue breakdown for Recursion Pharmaceuticals, Inc. Class A (BIVA:RXRX). The company generated 1.34 billion MXN last year, with its Drug Discovery segment contributing the most at 1.35 billion MXN. The United States was the largest regional contributor, accounting for 709.28 million MXN.
RXRX (RXRX) insider details 50,000-share planned sale and recent stock trades
Christopher C. Gibson, an insider at RXRX, plans to sell 50,000 Class A shares of Recursion Pharmaceuticals (RXRX) via Fidelity Brokerage Services LLC on NASDAQ, valued at approximately $152,702.73. These shares were originally acquired as founder's compensation in 2021. The filing also details numerous prior Class A share sales by Gibson and related entities, including the Gibson Family Trust and Lahwran-3 LLC, over the past three months, with significant aggregate proceeds.